Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    24131140 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Albumin-bound paclitaxel (ABI-007);   Drug: Gemcitabine
2 Active, not recruiting Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: Nab-Paclitaxel and Gemcitabine
3 Recruiting Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Conditions: Cancer;   Pancreatic Cancer
Interventions: Procedure: Tumour Biopsy;   Other: Serial Collection of Plasma, Serum and Urine Samples
4 Completed A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
Condition: Pancreatic Cancer
Intervention: Drug: ABI-007

Study has passed its completion date and status has not been verified in more than two years.